Giselle Debs
Internal Medicine · Pembroke Pines, FLNPI 1538457304
Payments from drug & device makers
Across 1,099 payments — averaging $1585.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$679K
- AbbVie$261K
- Teva Pharmaceuticals USA, Inc.$170K
- Sanofi US Services Inc.$168K
- Biohaven Pharmaceuticals, Inc.$119K
- GSK$116K
- plus $229K from 10 others
Across 7 payments — averaging $97.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$684
What the payments were for
- Food & beverage$110100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 33 | $679,189 |
| AbbVie | 50 | $260,900 |
| Teva Pharmaceuticals USA, Inc. | 712 | $170,153 |
| Sanofi US Services Inc. | 30 | $168,093 |
| Biohaven Pharmaceuticals, Inc. | 37 | $119,370 |
| GSK | 19 | $115,751 |
| Esperion Therapeutics, Inc. | 163 | $93,161 |
| Vanda Pharmaceuticals Inc. | 25 | $67,785 |
| Genentech, Inc. | 16 | $16,636 |
| Bristol Myers Squibb | 4 | $13,328 |
| Lexicon Pharmaceuticals, Inc. | 1 | $12,225 |
| Novartis | 1 | $10,670 |
| Vifor (international) Ltd. | 2 | $6,750 |
| AstraZeneca | 2 | $3,289 |
| Eli Lilly | 2 | $3,265 |
| Kowa Research Institute, Inc. | 2 | $2,222 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FARXIGA$110
How this compares
$1,742,787 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TradjentaLinagliptin | 230 | $115,585 |
| EliquisApixaban | 159 | $87,913 |
| XareltoRivaroxaban | 113 | $61,017 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $41,938 |
| TrulicityDulaglutide | 31 | $38,274 |
| EntrestoSacubitril/Valsartan | 48 | $31,582 |
| JentaduetoLinagliptin/Metformin Hcl | 58 | $28,986 |
| LinzessLinaclotide | 40 | $20,677 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 43 | $20,604 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 194 | $19,080 |
| Pregabalin | 126 | $14,343 |
| BrilintaTicagrelor | 30 | $12,796 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 82 | $11,710 |
| Insulin Aspart FlexpenInsulin Aspart | 64 | $11,176 |
| FarxigaDapagliflozin Propanediol | 20 | $11,064 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $679,189 | $61,017113 claims |
| NovartisEntresto | $10,670 | $31,58248 claims |
| AbbVieLinzess, Synthroid | $260,900 | $28,413222 claims |
| AstraZenecaBrilinta, Farxiga | $3,289 | $23,85950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.
Other internal medicine in Pembroke Pines
- Jaynier MoyaPembroke Pines$45.4M
- Yanely Pineiro PueblaPembroke Pines$12.4M
- Armando de FeriaPembroke Pines$11.8M
- Maria BermudezPembroke Pines$10.2M
- Robert PerryPembroke Pines$9.2M
- Ernesto FuentesPembroke Pines$9M
- Giralt Yanez RamosPembroke Pines$5.5M
- Kenneth BlazePembroke Pines$4.3M
- Reynold Duarte MartinezPembroke Pines$4.1M
- Yaneicy Gonzalez RojasCoral Gables$93.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.